Description
Researchers have developed a hybrid compound that prevents metronidazole and similar antibiotics from being absorbed by the body before reaching the location of infection, thus avoiding the toxicity associated with higher doses of metronidazole. These hybrid compounds are not only effective in treating C. diff but other bacterial and parasitic infections such as Clostridium perfringen and Helicobacter pylori, and potentially Crohn’s disease and other inflammatory bowel diseases. This technology is being actively marketed by the co-owner, the University of Texas, Arlington.
Keywords
Colostridium Difficile, Chrohn’s, IBS
Granted Patents or Published Applications
Related Scientific References
Licensing Opportunities
Please contact us or UT Arlington (otm@uta.edu) if interested in licensing
Related Links
Technologies
- Compounds for Treatment of BCR-ABL + Lymphoblastic Leukemias (using an existing malaria drug to overcome resistance) (SJ-11-0042)
- DON and small molecule Bcl-2 family antagonists treating glutamine addicted cell lines for Neuroblastomas and Ewing sarcomas (SJ-13-0026)
- Improved Human Carboxylesterase for Therapy with CPT-11 (SJ-06-0006)
- Methods for Diagnosing and Treating Learning or Mental Disorders with the SERCA2 Protein and miRNAs that regulate SERCA2 Levels (SJ-10-0003 and SJ-12-0020)
- New Uses for Chloroquine and Chloroquine Analogs (SJ-02-0008 and SJ-05-0017)
- Novel Carboxylesterase Inhibitors (SJ-02-0030)
- Sudemycins: Synthetic Natural Product Analogs as Anti-Cancer Agents (SJ-08-0026 & SJ-13-0007)
- Therapeutic Leads Targeting Influenza Endonuclease (SJ-09-0041)
- Treating Cochlear Hearing loss with p27Kip1/Atoh1 Combinations (SJ-13-0019)
- Use of metabolic drugs to treat influenza infection (SJ-14-0040)
- Use of small molecule ER stress modulators to treat tumors with active Sonic Hedgehog (SHH) signaling due to Smoothened (SMO) mutation (SJ-12-0038)
- Use of specific retinoid receptor agonists and antagonists as cancer therapies (SJ-14-0011)
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.